| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
Until now, no studies investigating the in vivo metabolic behaviour of omeprazole enantiomers have been reported. The three major metabolites of omeprazole, known as (R)-,(S)-5-hydroxyomeprazole and omeprazole sulfone, are mainly metabolised by cytochrome P450 (CYP) 2C19 and CYP3A4, respectively. The clinical efficacy of Helicobacter Pylori eraducation is closely related to the CYP2C19 phenotypes, as evidenced by studies in patients receiving omeprazole. In the present study, we constructed a simple and sensitive high-performance liquid chromatography (HPLC) UV method and it used in pharmacokinetic studies of (R)- and (S)-omeprazole and their chiral metabolites in relation to the CYP2C19 genotypes. Conceqently, CYP2C19 genotypes were clarified and the prediction of CYP2C19 genotypes by using limited plasma concentration of omeprazole enantiomers may be a important tool in clinical situation.
|
